IDEXX Laboratories, Inc.: EPS $3.96 vs $3.73 expected; revenue $1.21B vs $1.19B
Key Facts
Q3 FY2026 results
| Metric | Actual | Estimate | Surprise | Year ago |
|---|---|---|---|---|
| EPS (USD) | 3.96 | 3.73 | +6.2% | 3.40 |
| Revenue (USD bn) | 1.21 | 1.19 | +1.9% | 1.11 |
Recent reports: actual vs estimate
| Reported | Period | EPS (USD) | Estimate | Surprise | Revenue (USD bn) | Estimate | Surprise |
|---|---|---|---|---|---|---|---|
| Nov 2, 2026 | Q3 FY2026 | 3.96 | 3.73 | +6.2% | 1.21 | 1.19 | +1.9% |
| Aug 4, 2026 | Q2 FY2026 | 4.27 | 3.94 | +8.4% | 1.22 | 1.20 | +1.4% |
| May 5, 2026 | Q1 FY2026 | 3.47 | 3.41 | +1.8% | 1.14 | 1.12 | +2.0% |
| Feb 2, 2026 | Q4 FY2025 | 3.08 | 2.93 | +5.1% | 1.09 | 1.07 | +1.7% |
| Nov 3, 2025 | Q3 FY2025 | 3.40 | 3.14 | +8.3% | 1.11 | 1.07 | +3.0% |
| Aug 4, 2025 | Q2 FY2025 | 3.63 | 3.28 | +10.7% | 1.11 | 1.06 | +4.4% |
| May 1, 2025 | Q1 FY2025 | 2.96 | 2.85 | +3.9% | 1.00 | 1.00 | +0.1% |
| Feb 3, 2025 | Q4 FY2024 | 2.62 | 2.39 | +9.6% | 0.95 | 0.94 | +2.0% |
Source: Figures from the EL7 database. Estimates are the analyst consensus carried by our data vendor (FMP), not official figures.
IDEXX Laboratories, Inc. results: EPS $3.96 vs $3.73 expected; revenue $1.21B vs $1.19B. The results cover the company's Q3 FY2026. EPS came in above analysts' estimate by 6.2%; revenue above the estimate by 1.9%.
Revenue was up 9.9% from $1.11 billion a year earlier (Q3 FY2025). EPS was up 16.5% from $3.40 a year earlier. On its record, EPS topped analysts' estimates in 7 of 7 earlier comparable reports.
What the results mean
Revenue growth indicates an expanding business at IDEXX Laboratories, while understanding the quality of that growth requires examining its sources across diagnostic services and veterinary products. The business combines instrument sales with the consumables, tests, and laboratory services associated with their use.
The companion animal business supports veterinarians through in-clinic diagnostics, reference laboratories, consultation, and practice management software. This range makes test utilization and ongoing demand for consumables and services important business drivers, alongside instrument purchases.
The company also operates in water quality testing, livestock and poultry diagnostics, and dairy herd health monitoring. These activities serve needs distinct from veterinary practices, making the distribution of growth across business areas important to interpreting the results.
What to watch on the earnings call: The earnings call merits attention to management's discussion of demand across instruments, consumables, and laboratory services, and how actively veterinary practices use diagnostic tools. Other useful topics include the effect of the product and service mix on margins, spending on diagnostic development, and the contribution of water testing and livestock, poultry, and dairy activities to business growth.
For the full analysis of IDEXX Laboratories, Inc. stock — valuation, scores and financial statements — see the stock page linked with this story.